Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP, Controller | February 27, 2026 | March 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 11, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 8,468 |
Reported balance
After 2026-02-27 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 2,108 · Balance 8,468 |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 543 |
Reported balance
Holding disclosure · report date 2026-02-27 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 543 F1: Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 6, 2026 17:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,230 | $233.56 | $1,221,518.80 |
DisclosureSEC source: 0002057696-26-000008 · form4-03062026_100340.xml · nonDerivative · entry 1 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,654 Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,692 | $232.08 | $624,759.36 |
DisclosureSEC source: 0002057696-26-000004 · form4-03032026_060303.xml · nonDerivative · entry 1 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,884 Read SEC document |
| February 27, 2026 Filed Mar 11, 2026 17:00 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,108 | $232.08 | $489,224.64 |
DisclosureSEC source: 0002057696-26-000010 · form4a-03112026_050317.xml · nonDerivative · entry 1 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,468 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 18:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 4,875 | $0.00 Strike: $230.04 | $0.00 |
DisclosureSEC source: 0002057696-26-000002 · form4-02202026_060215.xml · derivative · entry 6 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,875 Underlying: Common Stock · 4,875 shares Expires 2036-02-17 F6 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 1,625 on February 18, 2027, 1,625 on February 18, 2028, and 1,625 on February 18, 2029. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 18:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,384 | $0.00 | $0.00 |
DisclosureSEC source: 0002057696-26-000002 · form4-02202026_060215.xml · nonDerivative · entry 4 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,576 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 18:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0002057696-26-000002 · form4-02202026_060215.xml · nonDerivative · entry 3 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,192 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 18:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0002057696-26-000002 · form4-02202026_060215.xml · nonDerivative · entry 2 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 18:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,505 | $0.00 | $0.00 |
DisclosureSEC source: 0002057696-26-000002 · form4-02202026_060215.xml · nonDerivative · entry 1 Purdue David Ryan · CIK 0002057696 · SVP, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,010 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.